We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Elevance Health's Q4 Earnings Beat Estimates on Rising Premiums
Read MoreHide Full Article
Elevance Health, Inc. (ELV - Free Report) reported fourth-quarter 2024 adjusted earnings per share (EPS) of $3.84, which surpassed the Zacks Consensus Estimate by 1.1%. However, the bottom line deteriorated 31.7% year over year.
Operating revenues of $45 billion rose 6% year over year. Moreover, the top line beat the consensus mark by a whisker.
Better-than-expected quarterly results benefited from rising premiums and product revenues. Rising expenses and a decline in Medicaid and Medicare memberships partially offset the positives.
Full-Year Results of ELV
ELV’s 2024 revenues of $175.2 billion increased from $170.2 billion a year ago due to higher premium yields and higher CarelonRx product revenue.
Full-year 2024 EPS of $33.04 declined from $33.14 in 2023.
Elevance Health, Inc. Price, Consensus and EPS Surprise
Medical membership of Elevance Health was around 45.7 million as of Dec. 31, 2024, which slipped 2% year over year. The decrease was due to attrition in its Medicaid business, partially offset by growth in commercial fee-based and Affordable Care Act membership. The reported figure missed the Zacks Consensus Estimate of 46 million and our estimate of 45.9 million.
Premiums increased 3.2% year over year to $36.2 billion but came lower than the consensus mark of $36.6 billion. Product revenues of $6.7 billion increased 24.5% year over year and came higher than the Zacks Consensus Estimate of $5.9 billion and our estimate of $5.6 billion.
Net investment income declined 0.4% year over year to $527 million, which missed the consensus mark of $532.4 million. Total operating margin deteriorated 150 basis points (bps) year over year to 1.5%.
Total expenses of $44.8 billion rose 7.7% year over year and were higher than our estimate of $42.8 billion. The year-over-year rise was due to higher benefit expenses, the cost of products sold, and interest expenses.
The operating expense ratio improved 110 bps year over year to 10.7%. The benefit expense ratio of 92.4% deteriorated 320 bps year over year.
Segmental Results
Health Benefits
Operating revenues totaled $37.6 billion, which increased 3% year over year but missed the Zacks Consensus Estimate of $38.2 billion. The metric benefited from higher premium yields, partially offset by the membership decline in Medicaid.
Operating gain declined 75% year over year to $0.2 billion, lower than the consensus mark of $0.4 billion. The operating margin of 0.6% deteriorated 150 bps year over year.
Carelon
The segment’s operating revenues amounted to $14.7 billion, which rose 19% year over year. The uptick was due to the introduction and expansion of risk-based medical benefits within Carelon Services and acquisitions. The reported figure outpaced the Zacks Consensus Estimate of $14.1 billion and our estimate of $12.9 billion.
The unit’s operating gain of $0.6 billion remained stable year over year and missed the consensus mark of $0.7 and our estimate of $0.63 billion. The operating margin deteriorated 90 bps year over year to 3.9%.
Corporate & Other
Operating revenues came in at negative $14 million in the fourth quarter. The unit incurred an operating loss of $102 million, wider than the prior-year quarter’s loss of $75 million.
Financial Details (as of Dec. 31, 2024)
Elevance Health exited the fourth quarter with cash and cash equivalents of $8.3 billion, which rose 27% from the 2023-end level. Total assets of $116.7 billion increased 7.1% from the figure at 2023-end.
Long-term debt, less the current portion, amounted to $29.2 billion, up 25.7% from the figure as of Dec. 31, 2023. Short-term borrowings at the fourth-quarter end were $365 million, while the current portion of the long-term debt amounted to $1.6 billion.
Total equity of $41.4 billion grew 5.1% from the 2023-end level.
ELV generated net cash flow from operations of $5.8 billion in 2024, declining 27.9% year over year.
Capital Deployment Update
Elevance Health bought back shares worth $1.8 billion in the fourth quarter. It had a leftover capacity of around $9.3 billion under its share buyback authorization as of Dec. 31, 2024.
ELV paid a quarterly dividend of $1.63 per share, adding up to a cash distribution worth $373 million.
2025 Outlook
Adjusted EPS is anticipated to be between $34.15 and $34.85, up from the 2024 reported figure of $33.04 per share. GAAP EPS is currently projected to be between $30.4 and $31.1. The operating margin for the Health Benefits segment is estimated to witness a decrease of 50-25 basis points (bps) from the 2024 reported figure of 4.2%. Also, the operating margin for CarelonRx is expected to see 0-20 bps growth, while the same for Carelon Services is estimated to witness a decrease of 100-50 bps.
Management expects operating revenues to witness high single to low double-digit growth in 2025 from $175.2 billion in 2024. Premium revenues are estimated to witness low double-digit growth in 2025 from the 2024 level of $144.2 billion. Medical enrolment is forecasted to be between 45.8 and 46.7 million in 2025, up from 45.7 million in 2024.
Net investment income is anticipated to be $1.9 billion, down from $2.1 billion in 2024. Interest expenses are forecasted to be $1.5 billion in 2025 while operating cash flow is likely to be approximately $8 billion. Diluted shares are estimated to decline to 225-226 million from 232.9 million at 2024-end.
ELV’s Zacks Rank
Elevance Health currently carries a Zacks Rank #3 (Hold).
A Medical Sector Release
Of the Medical sector players that have reported fourth-quarter results so far, the bottom line of UnitedHealth Group Incorporated (UNH - Free Report) beat the Zacks Consensus Estimate.
UnitedHealth Group reported a fourth-quarter 2024 adjusted EPS of $6.81, which surpassed the Zacks Consensus Estimate of $6.71. The bottom line increased 10.6% year over year. Revenues rose 6.8% year over year to $100.8 billion. The top line missed the consensus mark by 1.4%.
UNH’s operating earnings grew 1.1% year over year to $7.8 billion. The net margin deteriorated 30 bps year over year to 5.5%. Revenues of the health benefits business of UnitedHealth, UnitedHealthcare, rose 4.7% year over year to $74.1 billion on the back of an increase in domestic membership growth.
The Zacks Consensus Estimate for LifeStance’s 2024 earnings indicates a 60.8% year-over-year improvement. LFST beat earnings estimates in three of the trailing four quarters and missed once, with an average surprise of 21.4%. The consensus mark for revenues implies 17.3% growth from the year-ago period.
The Zacks Consensus Estimate for Medpace’s 2024 earnings implies a 34.4% increase from the year-ago reported figure. MEDP beat earnings estimates in each of the trailing four quarters, with an average surprise of 14.7%. The consensus mark for its current-year revenues is pegged at $2.1 billion, which indicates an 11.8% year-over-year increase.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Elevance Health's Q4 Earnings Beat Estimates on Rising Premiums
Elevance Health, Inc. (ELV - Free Report) reported fourth-quarter 2024 adjusted earnings per share (EPS) of $3.84, which surpassed the Zacks Consensus Estimate by 1.1%. However, the bottom line deteriorated 31.7% year over year.
See the Zacks Earnings Calendar to stay ahead of market-making news.
Operating revenues of $45 billion rose 6% year over year. Moreover, the top line beat the consensus mark by a whisker.
Better-than-expected quarterly results benefited from rising premiums and product revenues. Rising expenses and a decline in Medicaid and Medicare memberships partially offset the positives.
Full-Year Results of ELV
ELV’s 2024 revenues of $175.2 billion increased from $170.2 billion a year ago due to higher premium yields and higher CarelonRx product revenue.
Full-year 2024 EPS of $33.04 declined from $33.14 in 2023.
Elevance Health, Inc. Price, Consensus and EPS Surprise
Elevance Health, Inc. price-consensus-eps-surprise-chart | Elevance Health, Inc. Quote
Q4 Operational Update
Medical membership of Elevance Health was around 45.7 million as of Dec. 31, 2024, which slipped 2% year over year. The decrease was due to attrition in its Medicaid business, partially offset by growth in commercial fee-based and Affordable Care Act membership. The reported figure missed the Zacks Consensus Estimate of 46 million and our estimate of 45.9 million.
Premiums increased 3.2% year over year to $36.2 billion but came lower than the consensus mark of $36.6 billion. Product revenues of $6.7 billion increased 24.5% year over year and came higher than the Zacks Consensus Estimate of $5.9 billion and our estimate of $5.6 billion.
Net investment income declined 0.4% year over year to $527 million, which missed the consensus mark of $532.4 million. Total operating margin deteriorated 150 basis points (bps) year over year to 1.5%.
Total expenses of $44.8 billion rose 7.7% year over year and were higher than our estimate of $42.8 billion. The year-over-year rise was due to higher benefit expenses, the cost of products sold, and interest expenses.
The operating expense ratio improved 110 bps year over year to 10.7%. The benefit expense ratio of 92.4% deteriorated 320 bps year over year.
Segmental Results
Health Benefits
Operating revenues totaled $37.6 billion, which increased 3% year over year but missed the Zacks Consensus Estimate of $38.2 billion. The metric benefited from higher premium yields, partially offset by the membership decline in Medicaid.
Operating gain declined 75% year over year to $0.2 billion, lower than the consensus mark of $0.4 billion. The operating margin of 0.6% deteriorated 150 bps year over year.
Carelon
The segment’s operating revenues amounted to $14.7 billion, which rose 19% year over year. The uptick was due to the introduction and expansion of risk-based medical benefits within Carelon Services and acquisitions. The reported figure outpaced the Zacks Consensus Estimate of $14.1 billion and our estimate of $12.9 billion.
The unit’s operating gain of $0.6 billion remained stable year over year and missed the consensus mark of $0.7 and our estimate of $0.63 billion. The operating margin deteriorated 90 bps year over year to 3.9%.
Corporate & Other
Operating revenues came in at negative $14 million in the fourth quarter. The unit incurred an operating loss of $102 million, wider than the prior-year quarter’s loss of $75 million.
Financial Details (as of Dec. 31, 2024)
Elevance Health exited the fourth quarter with cash and cash equivalents of $8.3 billion, which rose 27% from the 2023-end level. Total assets of $116.7 billion increased 7.1% from the figure at 2023-end.
Long-term debt, less the current portion, amounted to $29.2 billion, up 25.7% from the figure as of Dec. 31, 2023. Short-term borrowings at the fourth-quarter end were $365 million, while the current portion of the long-term debt amounted to $1.6 billion.
Total equity of $41.4 billion grew 5.1% from the 2023-end level.
ELV generated net cash flow from operations of $5.8 billion in 2024, declining 27.9% year over year.
Capital Deployment Update
Elevance Health bought back shares worth $1.8 billion in the fourth quarter. It had a leftover capacity of around $9.3 billion under its share buyback authorization as of Dec. 31, 2024.
ELV paid a quarterly dividend of $1.63 per share, adding up to a cash distribution worth $373 million.
2025 Outlook
Adjusted EPS is anticipated to be between $34.15 and $34.85, up from the 2024 reported figure of $33.04 per share. GAAP EPS is currently projected to be between $30.4 and $31.1. The operating margin for the Health Benefits segment is estimated to witness a decrease of 50-25 basis points (bps) from the 2024 reported figure of 4.2%. Also, the operating margin for CarelonRx is expected to see 0-20 bps growth, while the same for Carelon Services is estimated to witness a decrease of 100-50 bps.
Management expects operating revenues to witness high single to low double-digit growth in 2025 from $175.2 billion in 2024. Premium revenues are estimated to witness low double-digit growth in 2025 from the 2024 level of $144.2 billion. Medical enrolment is forecasted to be between 45.8 and 46.7 million in 2025, up from 45.7 million in 2024.
Net investment income is anticipated to be $1.9 billion, down from $2.1 billion in 2024. Interest expenses are forecasted to be $1.5 billion in 2025 while operating cash flow is likely to be approximately $8 billion. Diluted shares are estimated to decline to 225-226 million from 232.9 million at 2024-end.
ELV’s Zacks Rank
Elevance Health currently carries a Zacks Rank #3 (Hold).
A Medical Sector Release
Of the Medical sector players that have reported fourth-quarter results so far, the bottom line of UnitedHealth Group Incorporated (UNH - Free Report) beat the Zacks Consensus Estimate.
UnitedHealth Group reported a fourth-quarter 2024 adjusted EPS of $6.81, which surpassed the Zacks Consensus Estimate of $6.71. The bottom line increased 10.6% year over year. Revenues rose 6.8% year over year to $100.8 billion. The top line missed the consensus mark by 1.4%.
UNH’s operating earnings grew 1.1% year over year to $7.8 billion. The net margin deteriorated 30 bps year over year to 5.5%. Revenues of the health benefits business of UnitedHealth, UnitedHealthcare, rose 4.7% year over year to $74.1 billion on the back of an increase in domestic membership growth.
Key Picks
Some better-ranked and promising stocks in the broader Medical sector areLifeStance Health Group, Inc. (LFST - Free Report) and Medpace Holdings, Inc. (MEDP - Free Report) , each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The Zacks Consensus Estimate for LifeStance’s 2024 earnings indicates a 60.8% year-over-year improvement. LFST beat earnings estimates in three of the trailing four quarters and missed once, with an average surprise of 21.4%. The consensus mark for revenues implies 17.3% growth from the year-ago period.
The Zacks Consensus Estimate for Medpace’s 2024 earnings implies a 34.4% increase from the year-ago reported figure. MEDP beat earnings estimates in each of the trailing four quarters, with an average surprise of 14.7%. The consensus mark for its current-year revenues is pegged at $2.1 billion, which indicates an 11.8% year-over-year increase.